Proposed Zofran (ondansetron) MDL Grows as Venue Remains Undecided

As GlaxoSmithKline (“GSK”) pushes for all Zofran (ondansetron) cases filed to be centralized in a multi-district litigation (“MDL”) in the Eastern District of Pennsylvania, where the drug company has operations, many plaintiffs oppose the venue, citing an overload of cases already pending in the Philadelphia court.  Approximately 36 cases filed in more than 20 different courts around the country—the first of them filed by plaintiffs’ law firm Grant & Eisenhofer—all allege similar claims that GSK engaged in “off-label” marketing of Zofran (ondansetron) and did not adequately warn the public and medical community that Zofran taken during pregnancy may cause birth defects such as heart malformations and cleft palate.  First developed to treat severe nausea and vomiting in cancer patients, Zofran (ondansetron) has never been approved by the FDA for use in pregnant women to alleviate morning sickness. Grant & Eisenhofer continues to file cases on behalf of families whose children were born with birth defects when exposed to the anti-nausea drug, adding to the pressure GSK faces in the pending MDL.

Real Time Analytics